News

An investigation has uncovered evidence of significant misreporting, raising new concerns about the approval and long-term ...
Fresh concerns have emerged about the platelet studies underpinning the FDA approval of ticagrelor, AstraZeneca's ...
As generic versions of AstraZeneca’s blockbuster drug ticagrelor prepare to enter the market, The BMJ raises fresh concerns over the integrity of the clinical trials that underpinned its approval.
In a follow up investigation into the multibillion dollar drug ticagrelor, The BMJ has uncovered fresh concerns, this time in ...
Ticagrelor may be a more effective antiplatelet therapy than aspirin for the prevention of recurrent stroke and cardiovascular events in patients with acute cerebral ischemia. We conducted an ...
Ticagrelor reversibly inhibits the P2Y12 receptors on platelets, preventing platelet activation and, consequently, aggregation. Unlike the thienopyridines, it does not require metabolic activation.
MEDICS have raised concerns over a drug taken by millions to prevent heart attacks and strokes, claiming key safety data was “misreported” by its manufacturer AstraZeneca.
Experts suggest that ticagrelor provides considerable added benefit to specific patients by decreasing the risk of death and myocardial infarction. Share: Facebook Twitter Pinterest LinkedIN Email.
Ticagrelor monotherapy after 3-month dual antiplatelet therapy was not associated with greater risk for repeat revascularization or MACCE at 1 year after PCI vs. continued DAPT, a speaker reported.
Ticagrelor is a direct-acting antiplatelet agent that does not depend on metabolic activation and that "reversibly binds" and inhibits the P2Y12 receptor on platelets.
A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major ...